Financials data is unavailable for this security.
View more
Year on year Jiang Zhong Pharmaceutical Co Ltd grew revenues 13.00% from 3.89bn to 4.39bn while net income improved 18.40% from 598.24m to 708.29m.
| Gross margin | 63.72% |
|---|---|
| Net profit margin | 19.56% |
| Operating margin | 23.08% |
| Return on assets | 13.36% |
|---|---|
| Return on equity | 19.31% |
| Return on investment | 20.72% |
More ▼
Cash flow in CNYView more
In 2023, Jiang Zhong Pharmaceutical Co Ltd increased its cash reserves by 16.68%, or 91.82m. The company earned 1.04bn from its operations for a Cash Flow Margin of 23.60%. In addition the company used 127.03m on investing activities and also paid 817.05m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.91 |
|---|---|
| Tangible book value per share | 5.22 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.13 |
|---|---|
| Quick ratio | 0.8833 |
| Total debt/total equity | 0.0005 |
|---|---|
| Total debt/total capital | 0.0004 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 13.04% and 17.89%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 5.42% |
|---|---|
| Div growth rate (5 year) | 40.99% |
| Payout ratio (TTM) | 108.64% |
| EPS growth(5 years) | 8.45 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.93 |
More ▼
